Human platelet lysate (or hPL) is a substitute supplement for fetal bovine serum (FBS) in experimental and clinical cell culture.
The included clotting factors require to add heparin to the cell culture media to prevent coagulation during incubation.
Platelet lysate is commonly used for supplementation of basal media in mesenchymal stem cells culture.
[3] Human platelet lysate is available commercially through AventaCell BioMedical, Elk Bioscience, Mill Creek Life Sciences, Compass Biomedical, Inc., Sexton Biotechnologies, Macopharma SA, iBiologics, PL BioScience GmbH, Life Science Group Ltd (UK) and Trinova Biochem GmbH under the product lines UltraGRO, PLTMax, PLUS, Stemulate, Human Platelet Lysate, XcytePlus, PLSOLUTION, PLMATRIX and CRUX RUFA Media Supplements.
Platelet lysate has also been produced with non-human animal material and has been made commercially available by Agulos Biotech (porcine) and Japan Biomedical (bovine).
Platelet lysate has been tested in various cell culture applications including use in advanced bioreactor systems.